Genomics Reloaded: Rise of the Expression Profiles

Comment

Gregory N Gan et al. Int J Radiat Oncol Biol Phys. 2018.

. 2018 May 1;101(1):1-3.

doi: 10.1016/j.ijrobp.2017.10.023.

No abstract available

Comment on

Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab.
Bossi P, Bergamini C, Siano M, Cossu Rocca M, Sponghini AP, Favales F, Giannoccaro M, Marchesi E, Cortelazzi B, Perrone F, Pilotti S, Locati LD, Licitra L, Canevari S, De Cecco L. Bossi P, et al. Clin Cancer Res. 2016 Aug 1;22(15):3961-70. doi: 10.1158/1078-0432.CCR-15-2547. Epub 2016 Feb 26. Clin Cancer Res. 2016. PMID: 26920888
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB, Torres-Roca JF. Scott JG, et al. Lancet Oncol. 2017 Feb;18(2):202-211. doi: 10.1016/S1470-2045(16)30648-9. Epub 2016 Dec 18. Lancet Oncol. 2017. PMID: 27993569 Free PMC article.
Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
Klinghammer K, Otto R, Raguse JD, Albers AE, Tinhofer I, Fichtner I, Leser U, Keilholz U, Hoffmann J. Klinghammer K, et al. Int J Cancer. 2017 Sep 15;141(6):1215-1221. doi: 10.1002/ijc.30808. Epub 2017 Jun 21. Int J Cancer. 2017. PMID: 28560858

1. Bossi P, et al., Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. Clin Cancer Res, 2016. 22(15): p. 3961–70. - PubMed
1. Klinghammer K, et al., Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer. Int J Cancer, 2017. 141(6): p. 1215–1221. - PubMed
1. Scott JG, et al., A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol, 2017. 18(2): p. 202–211. - PMC - PubMed
1. Kimple RJ, et al., Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res, 2013. 19(4): p. 855–64. - PMC - PubMed
1. Keysar SB, et al., A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol, 2013. 7(4): p. 776–90. - PMC - PubMed